Ionis Pharmaceuticals Inc  

(Public, NASDAQ:IONS)   Watch this stock  
Find more results for NASDAQ:ISIS
38.98
+1.05 (2.77%)
Mar 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 38.03 - 39.30
52 week 19.59 - 57.00
Open 38.11
Vol / Avg. 1.50M/2.06M
Mkt cap 4.96B
P/E     -
Div/yield     -
EPS -0.72
Shares 123.75M
Beta 2.55
Inst. own 89%
Feb 23, 2017
Q4 2016 Ionis Pharmaceuticals Inc Earnings Release (Estimated)
Jan 9, 2017
Ionis Pharmaceuticals Inc at JPMorgan Healthcare Conference
Jan 5, 2017
Ionis Pharmaceuticals Inc Pipeline Update Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 16.13% -24.97%
Operating margin 23.18% -14.51%
EBITD margin - -10.76%
Return on average assets 11.82% -9.31%
Return on average equity 86.74% -57.64%
Employees 435 -
CDP Score - -

Address

2855 Gazelle Ct
CARLSBAD, CA 92010-6670
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 61
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President, Legal, General Counsel and Corporate Secretary
Age: 42
Bio & Compensation  - Reuters
C. Frank Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 59
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 58
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 54
Bio & Compensation  - Reuters
Sarah Boyce Chief Business Officer
Age: 44
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters